Tracking Trends in Biotechnology
Microcapspeculators.com News Commentary
Aug 15, 2017, 08:30 ET
LAS VEGAS, August 15, 2017 /PRNewswire/ --
The healthcare sector is made up of several different industries, from pharmaceuticals to biotechnology to health insurance. Making predictions in this sector can be difficult as there are many variables working with and against each other at one time. It's important to track both negative and positive trends in healthcare companies. Investors who track these trends, make the best out of their predictions.
Certain trends in healthcare an investor should track include: the aging population and their healthcare needs, personalized medicine, the global reach of certain diseases, obesity and diabetes epidemic, and of course, technological advances. All of these trends mean different things in healthcare stock. Biotech companies are working tirelessly to address specific trends in human health, identifying the companies who are working with healthcare trends is key.
Some such companies include: Endonovo Therapeutics, Inc. (OTC: ENDV), Juno Therapeutics, Inc. (NASDAQ: JUNO), Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), Genocea Biosciences, Inc. (NASDAQ: GNCA), and TherapeuticsMD, Inc. (NYSE: TXMD)
Endonovo Therapeutics, Inc. (OTCQB: ENDV)
Market Cap: $7.3M, current share price: .028
ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They are addressing several healthcare trends with their electroceutical platform, which is a non-invasive, non-implantable device for treating inflammatory conditions in vital organs. Through the innovative research at ENDV, they are addressing most of the major healthcare trends by developing therapies to treat the aging population and addressing obesity and the complications that it entails, such as peripheral artery disease, heart disease, diabetic kidney disease and non-alcoholic steatohepatitis (NASH). Additionally, ENDV is working to address global diseases, kidney disease, and organ failure.
Tracking ENDV and their work in research and development (R&D) is something anyone interested in healthcare or biotech stocks should do. As their research correlates and ebbs and flows with healthcare trends. Some highlights regarding ENDV's R&D are below:
- Initial target is the treatment of ischemic heart disease and peripheral artery disease
- Several currently planned studies have been developed targeting inflammatory pathologies of renal origin which include: acute kidney injury and diabetic nephropathy.
- Only biotech currently developing a non-invasive, non-pharmacological approach for the treatment of NASH, an inflammatory condition in the liver due to a buildup of fat that can lead to cirrhosis and liver failure if left untreated
As ENDV moves forward and inches closer to announcing the results of their pre-clinical studies across their diverse technology platform, you'll want to stay up-to-date with their successes.
Other healthcare and biotech companies to review
Juno Therapeutics, Inc. (JUNO)
Market Cap: $3.021B, current share price: 28.30
JUNO, a clinical-stage cell immunotherapy company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer, has achieved recent milestones with its collaboration with Editas Medicine, Inc. (EDIT) This collaboration began over two years ago, the two companies are pursuing three research programs that aim to combine Editas Medicine's genome editing platform with Juno's CAR and TCR technologies.
Their most recent achievement relates to the improvement in the ability of T cells to overcome the tumor microenvironment. Editas Medicine will receive $2.5 million for achieving this milestone.
Eleven Biotherapeutics, Inc. (EBIO)
Market Cap: $35.2M, current share price: 1.425
EBIO is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform. They announced this week that they'll be hosting a live conference call to announce their Q2 financial results.
This is scheduled for 8:00 a.m. ET on Monday, August 14, 2017. To access the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) at least five minutes prior to the start time and refer to conference ID 63779857.
Genocea Biosciences, Inc. (GNCA)
Market Cap: $112.74M, current share price: 3.955
Similarly to JUNO and EDITS collaboration on moving research forward regarding T cells, GNCA's lead candidate is a novel T cell-directed immunotherapy for genital herpes. Today marks a horrible day for GNCA's performance on the stock market. GNCA's shares closed down 7.42% on Thursday with a little over 600,000 shares traded. The company reported second quarter financial results this week and reported a loss of $15.4 million.
On a per share basis, this was a loss of 54 cents while Wall Street was only expecting a loss of 46 cents. Keep a lookout for this stock as its performance is expected to continue to plummet.
TherapeuticsMD, Inc. (TXMD)
Market Cap: $1.15B, current share price: 5.630
TXMD, an innovative women's healthcare company, just received a formal General Advice Letter from the FDA stating that an initial review has been completed and requesting that the Company submit the additional endometrial safety information to the NDA for TX-004HR on or before September 18, 2017.
This is great news for TXMD although they've been ranked negatively in the HealthCare Sector. Investors who seek profit from falling equity prices should target TXMD. Short interest is extremely high for TXMD with more than 20% of shares on loan.
Email: [email protected]
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link:http://microcapspeculators.com/disclaimer/
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
FN Media Group, LLC
Share this article